15.93
전일 마감가:
$15.49
열려 있는:
$15.5
하루 거래량:
709.14K
Relative Volume:
0.51
시가총액:
$2.05B
수익:
$298.30M
순이익/손실:
$298.21M
주가수익비율:
7.3624
EPS:
2.1637
순현금흐름:
$166.93M
1주 성능:
-5.89%
1개월 성능:
+0.82%
6개월 성능:
-0.31%
1년 성능:
+113.79%
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
AUPH
Aurinia Pharmaceuticals Inc
|
15.94 | 2.01B | 298.30M | 298.21M | 166.93M | 2.1637 |
|
VRTX
Vertex Pharmaceuticals Inc
|
524.83 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
673.24 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
925.38 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.31 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace
Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca
Aurinia launches trial combining lupus nephritis treatments - Investing.com
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo
Aurinia launches trial combining lupus nephritis treatments By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals balances autoimmune drug focus and U.S. market ambitions - AD HOC NEWS
AUPHAurinia Pharmaceuticals Inc Latest SEC Filings - Finviz
Document - SEC.gov
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why - Yahoo Finance
If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity - Moomoo
Why (AUPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? - Insider Monkey
IKAP Forecast — Price Target — Prediction for 2027 - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Aurinia Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:AUPH) - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Enterprise value to EBIT forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Price to earnings forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
Aurinia Pharmaceuticals Inc. Actuals & Estimates (SWB:IKAP) - TradingView
AUPH Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Price to book forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
Price to sales forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
Price to book forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
5 Small Drug Stocks to Invest in Amid a Biotech Comeback - The Globe and Mail
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last? - Yahoo Finance
Aurinia Pharmaceuticals hits new 52-week high, shares extend strong NASDAQ run - AD HOC NEWS
Aurinia Pharmaceuticals stock hits 52-week high at 17.44 USD - Investing.com
Aurinia Pharmaceuticals stock hits 52-week high at 17.44 USD By Investing.com - Investing.com South Africa
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Understanding Momentum Shifts in (AUPH) - Stock Traders Daily
Aurinia Pharmaceuticals Stockanalyst focus and sector check at week’s end - AD HOC NEWS
How New LUPKYNIS Renal Outcomes Data Could Impact Aurinia Pharmaceuticals (AUPH) Investors - simplywall.st
Investors - Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Institutional Confidence - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating - ChartMill
Aurinia Pharmaceuticals and Four More Stocks See Activist Action - Barron's
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation - Yahoo Finance
Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options - Stock Titan
Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036 - Stock Titan
Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant - Stock Titan
Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67 - Stock Titan
Avoiding Lag: Real-Time Signals in (AUPH) Movement - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):